Health Care & Life Sciences » Biotechnology | Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
4.00
6.00
48.00
383.00
956.00
3,781
Gross Income
4.00
6.00
48.00
383.00
956.00
3,781
SG&A Expense
8,611.00
28,150.00
58,400.00
80,859.00
120,576.00
233,330
EBIT
8,615.00
28,156.00
58,448.00
81,242.00
121,532.00
237,111
Pretax Income
8,603.00
28,031.00
57,230.00
79,039.00
119,505.00
230,743
Income Tax
170.00
25.00
9.00
10.00
14.00
44
Consolidated Net Income
8,773.00
28,006.00
57,221.00
79,049.00
119,491.00
230,699
Net Income
8,773.00
28,006.00
57,221.00
79,049.00
119,491.00
230,699
Net Income After Extraordinaries
8,773.00
28,006.00
57,221.00
79,049.00
119,491.00
230,699
Net Income Available to Common
8,773.00
28,006.00
57,221.00
79,049.00
119,491.00
230,699
EPS (Basic)
0.37
5.62
2.24
2.75
4.00
5.27
Basic Shares Outstanding
23,851.20
4,985.50
25,583.30
28,732.00
29,863.00
43,811
EPS (Diluted)
0.37
5.62
2.24
2.75
4.00
5.27
Diluted Shares Outstanding
23,851.20
4,985.50
25,583.30
28,732.00
29,863.00
43,811
EBITDA
8,611.00
28,150.00
58,400.00
80,859.00
120,576.00
233,330
Non-Operating Interest Income
12.00
125.00
1,218.00
2,203.00
2,027.00
6,368

About Atara Biotherapeutics

View Profile
Address
611 Gateway Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.atarabio.com
Updated 07/08/2019
Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.